These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

766 related articles for article (PubMed ID: 15709010)

  • 21. A protective immune response in mice to viral components other than hemagglutinin in a live influenza A virus vaccine model.
    Horimoto T; Takada A; Iwatsuki-Horimoto K; Kawaoka Y
    Vaccine; 2004 Jun; 22(17-18):2244-7. PubMed ID: 15149783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long- and short-time immunological memory in different strains of mice given nasally an adjuvant-combined nasal influenza vaccine.
    Asanuma H; Fujihashi K; Miyakoshi T; Yoshikawa T; Fujita-Yamaguchi Y; Kojima N; Nakata M; Suzuki Y; Tamura S; Kurata T; Sata T
    Vaccine; 2007 Sep; 25(39-40):6975-80. PubMed ID: 17716790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant effect of Bacillus firmus on the expression of cytokines and toll-like receptors in mouse nasopharynx-associated lymphoid tissue (NALT) after intranasal immunization with inactivated influenza virus type A.
    Zanvit P; Tichopád A; Havlíčková M; Novotná O; Jirkovská M; Kološtová K; Cechová D; Julák J; Sterzl I; Prokešová L
    Immunol Lett; 2010 Nov; 134(1):26-34. PubMed ID: 20709105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucosal immunization with attenuated Shigella flexneri harboring an influenza hemagglutinin DNA vaccine protects mice against a lethal influenza challenge.
    Vecino WH; Quanquin NM; Martinez-Sobrido L; Fernandez-Sesma A; García-Sastre A; Jacobs WR; Fennelly GJ
    Virology; 2004 Aug; 325(2):192-9. PubMed ID: 15246259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies on the usefulness of intranasal inactivated influenza vaccines.
    Tamura S
    Vaccine; 2010 Aug; 28(38):6393-7. PubMed ID: 20493820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses.
    Lu X; Edwards LE; Desheva JA; Nguyen DC; Rekstin A; Stephenson I; Szretter K; Cox NJ; Rudenko LG; Klimov A; Katz JM
    Vaccine; 2006 Nov; 24(44-46):6588-93. PubMed ID: 17030078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Gupta NK; Tomar P; Sharma V; Dixit VK
    Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness.
    Bizanov G; Janakova L; Knapstad SE; Karlstad T; Bakke H; Haugen IL; Haugan A; Samdal HH; Haneberg B
    Scand J Immunol; 2005 Jun; 61(6):503-10. PubMed ID: 15963044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.
    Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine.
    Yang P; Tang C; Luo D; Zhan Z; Xing L; Duan Y; Jia W; Peng D; Liu X; Wang X
    Vet Microbiol; 2010 Nov; 146(1-2):17-23. PubMed ID: 20888151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
    Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Fang F; Zheng M; Chen Z
    Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus.
    Ichinohe T; Ainai A; Ami Y; Nagata N; Iwata N; Kawaguchi A; Suzaki Y; Odagiri T; Tashiro M; Takahashi H; Strayer DR; Carter WA; Chiba J; Tamura S; Sata T; Kurata T; Hasegawa H
    J Med Virol; 2010 Oct; 82(10):1754-61. PubMed ID: 20827774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mucosal vaccination against influenza: protection of pigs immunized with inactivated virus and ether-split vaccine.
    Lim YK; Takada A; Tanizaki T; Ozaki H; Okazaki K; Kida H
    Jpn J Vet Res; 2001 Feb; 48(4):197-203. PubMed ID: 11276584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge.
    Fu TM; Guan L; Friedman A; Schofield TL; Ulmer JB; Liu MA; Donnelly JJ
    J Immunol; 1999 Apr; 162(7):4163-70. PubMed ID: 10201942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC; Johansson BE
    Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines.
    Asahi Y; Yoshikawa T; Watanabe I; Iwasaki T; Hasegawa H; Sato Y; Shimada S; Nanno M; Matsuoka Y; Ohwaki M; Iwakura Y; Suzuki Y; Aizawa C; Sata T; Kurata T; Tamura S
    J Immunol; 2002 Mar; 168(6):2930-8. PubMed ID: 11884464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
    Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
    Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.